Regulatory Analysis

What Does the FDA Panel's July 2026 Compounding Recommendation Mean for BPC-157, TB-500, and KPV When Human Efficacy Data Are Absent?

The FDA advisory panel's July 2026 vote recommended against adding BPC-157, TB-500, and KPV to the 503A bulk drug substance list, citing the absence of adequate and well-controlled human trials for all three compounds. The recommendation is non-binding but signals that compounding pharmacies cannot rely on these substances meeting the agency's clinical-need standard.